LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akcijų sąrašas・MannKind Corp

MannKind Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

3.36 1.82

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.3

Max

3.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-671K -17M
Pardavimai	-22M 90M
P/E Sektoriaus vid.	140.5 49.701
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-18.431
Darbuotojai	591
EBITDA	5.9M 3.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+127.79% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	56M 924M
Ankstesnė atidarymo kaina	1.54
Ankstesnė uždarymo kaina	3.36

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

4.079 / 4.323 Palaikymas ir pasipriešinimas

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-22 16:33; UTC

Uždarbis

Pagrindinės rinkos jėgos

Webull Shares Slide on 1Q Loss, Soaring Costs

2026-05-22 21:10; UTC

Uždarbis

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026-05-22 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 19:47; UTC

Uždarbis

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026-05-22 19:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026-05-22 19:10; UTC

Rinkos pokalbiai

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026-05-22 18:38; UTC

Rinkos pokalbiai

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026-05-22 18:35; UTC

Įsigijimai, susijungimai, perėmimai

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026-05-22 18:09; UTC

Rinkos pokalbiai

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026-05-22 17:58; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

2026-05-22 17:54; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2026-05-22 17:54; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-22 17:54; UTC

Rinkos pokalbiai

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

2026-05-22 17:03; UTC

Rinkos pokalbiai

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

2026-05-22 16:54; UTC

Rinkos pokalbiai

Crypto Spot Volumes Fall 14% in April -- Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 16:16; UTC

Rinkos pokalbiai

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

2026-05-22 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-22 15:55; UTC

Rinkos pokalbiai

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

2026-05-22 15:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-22 15:42; UTC

Rinkos pokalbiai

Oil Continues as Leading Indicator for All Markets -- Market Talk

2026-05-22 15:35; UTC

Rinkos pokalbiai

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

127.79% į viršų

12 mėnesių prognozė

Vidutinis 7.54 USD 127.79%

Aukščiausias 10 USD

Žemiausias 4.75 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių MannKind Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.079 / 4.323Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.